GLP-1 drug shortages create US $1 billion shadow industry Release Time: 2024-09-03 News Source: PharmaCompass Author: SENOVALucas The shortage of glucagon-like peptide-1 (GLP-1) receptor agonists, such as Ozempic, Saxenda, Trulicity, Victoza, Mounjaro, and Zepbound, has been grabbing headlines
On Monday, February 9, Novo Nordisk filed a U.S
Call (318) 219-7867 or contact us via our website to schedule a free case evaluation regarding a Rybelsus lawsuit with Attorney Greenwald today.
For large manufacturers with broad portfolios, this creates leverage: a PBM that wants to exclude a competitors oncology drug, for example, may find the decision complicated if that competitor also supplies a dozen other products for which the PBMs plan sponsors have strong utilization
Heres what naturally boosts GLP-1 and GIP: Fiber-rich foods (beans, vegetables, oats) Chewing slowly and avoiding ultra-processed foods Sleeping well Moving your body daily Managing stress These are the true first-line therapies
cytotoxic agents and selected antiepileptic drugs (including valproate, carbamazepine, phenytoin, fosphenytoin, primidone, topiramate and phenobarbital)